McKesson Corporation $MCK Shares Purchased by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. grew its position in McKesson Corporation (NYSE:MCK) by 35.3% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,089 shares of the company’s stock after buying an additional 1,329 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in McKesson were worth $3,931,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in MCK. Solstein Capital LLC grew its holdings in shares of McKesson by 171.4% during the second quarter. Solstein Capital LLC now owns 38 shares of the company’s stock worth $28,000 after buying an additional 24 shares in the last quarter. State of Wyoming acquired a new position in McKesson during the second quarter worth about $29,000. GFG Capital LLC purchased a new stake in McKesson during the 2nd quarter valued at about $30,000. Delos Wealth Advisors LLC purchased a new stake in McKesson during the 2nd quarter valued at about $35,000. Finally, Abound Wealth Management raised its holdings in McKesson by 104.3% in the 3rd quarter. Abound Wealth Management now owns 47 shares of the company’s stock valued at $37,000 after acquiring an additional 24 shares during the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on MCK shares. Robert W. Baird set a $968.00 price target on McKesson in a report on Wednesday, January 14th. UBS Group raised their target price on McKesson from $920.00 to $980.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “buy (a-)” rating on shares of McKesson in a report on Monday, December 29th. Morgan Stanley reissued an “overweight” rating and issued a $966.00 price objective on shares of McKesson in a report on Thursday, January 29th. Finally, Wall Street Zen downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $918.93.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Q3 earnings beat and revenue growth — McKesson reported quarterly EPS above consensus and revenue up ~11.4% year‑over‑year, driven by higher gross profit and operating profit expansion. Business Wire: Q3 Results & Guidance
• Positive Sentiment: Raised FY‑2026 adjusted EPS guidance — Management increased full‑year adjusted EPS to $38.80–$39.20, signaling confidence in specialty drug and oncology/biopharma services growth that underpins margin outlook. Reuters: Boosts 2026 Profit Forecast
• Positive Sentiment: Market reaction — Street enthusiasm around the beat + guidance lift sent shares to multi‑year/all‑time highs and a strong intraday jump as analysts and investors re‑rate growth expectations. Investing.com: Stock Hits All‑Time High
• Neutral Sentiment: Analyst actions mixed — Some firms nudged price targets higher (Wells Fargo, Mizuho) but maintained neutral/equal‑weight stances, so analyst moves are not uniformly bullish. Zacks: Broker View on MCK
• Negative Sentiment: Operational cash‑flow weakness and balance‑sheet items — reporting flagged weaker operating cash flow versus last year and higher total liabilities, which could temper valuation upside if cash conversion doesn’t improve. Insider selling was also noted. QuiverQuant: EPS Beat but Weak Cash Flow

Insider Transactions at McKesson

In related news, EVP Thomas L. Rodgers sold 276 shares of McKesson stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.08% of the stock is owned by company insiders.

McKesson Stock Performance

McKesson stock opened at $959.34 on Friday. The company’s 50 day simple moving average is $827.03 and its 200-day simple moving average is $777.93. McKesson Corporation has a 1 year low of $570.51 and a 1 year high of $971.93. The company has a market capitalization of $118.41 billion, a price-to-earnings ratio of 27.59, a price-to-earnings-growth ratio of 1.35 and a beta of 0.40.

McKesson (NYSE:MCK) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 303.62%. The firm had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter last year, the firm earned $8.03 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Equities analysts expect that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, March 2nd. McKesson’s payout ratio is currently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.